September 28, 2018
Over the past few years, the health policy landscape in Brussels has been characterised by the member states’ intense request for greater access to medicines. The primary focus has been on how prices could be reduced to increase access. However, drug shortages have equally remained on the radar. In June 2016, the Dutch Council Conclusions on strengthening checks and balances on the pharmaceutical industry have stirred political developments that have led to the ongoing intellectual...